Diagnostic and prognostic values of upregulated SPC25 in patients with hepatocellular carcinoma

Abstract

Background Spindle pole body component 25 (SPC25) plays a vital role in many cellular processes, such as tumorigenesis. However, the clinical significance of SPC25 in hepatocellular carcinoma (HCC) has not been investigated. This study aimed to explore the expression patterns of SPC25 in HCC and non-neoplastic tissues and to investigate the diagnostic and prognostic values of SPC25. Method The expression of SPC25 was examined in 374 HCC issues and 50 non-neoplastic tissues from The Cancer Genome Atlas (TCGA) cohort. The diagnostic and prognostic values of SPC25 were analyzed via receiver operating characteristic (ROC) curve and survival analyses, respectively. Univariate and multivariate Cox regression analyses were used to identify the prognostic factors and to establish a nomogram. The diagnostic and prognostic values were further validated in an external cohort from the International Cancer Genome Consortium (ICGC) database. Results The expression of SPC25 in HCC tissues was significantly higher than that in normal tissues in both cohorts (all P < 0.001). The ROC curve analysis indicated that SPC25 expression has high diagnostic value in HCC with area under the curve (AUC) value of 0.969 (95% confidence interval [CI] [0.948–0.984]) and 0.945 (95% CI [0.920–0.965]) for TCGA and ICGC cohorts, respectively. Patients with HCC exhibiting high SPC25 expression were associated with worse prognosis than those exhibiting low SPC25 expression in both cohorts (all P < 0.001). SPC25 was independently associated with overall survival in both cohorts (all P < 0.001). The concordance indices of the nomogram for predicting overall survival in TCGA and ICGC cohorts were 0.647 and 0.805, respectively, which were higher than those of the American Joint Committee on Cancer (AJCC) staging system. Conclusion SPC25 was upregulated in HCC and independently predicted poor overall survival of patients with HCC. Therefore, SPC25 is an effective diagnostic and prognostic biomarker for HCC. An SPC25-based nomogram was more accurate and useful than the AJCC staging system to predict prognosis of HCC.

Identification of the HMMR Gene as a Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma Based on Integrated Bioinformatics Analysis

“…Despite the great advances in imaging techniques, surgical resection, percutaneous ablation, radiotherapy, and liver transplantation, the 5-year survival rate of HCC remains less than 20% because of the high postoperative recurrence rate and metastasis [5,6]. During the pathogenesis and progression of HCC, the expression of numerous genes has been aberrantly changed, including the activation of oncogenes and inactivation of tumor suppressor genes [7,8]. erefore, exploring more novel effective biomarkers for early diagnosis and precise prognostic prediction is urgently required.…”

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

“…Elevated expression of the NDC80 complex components, NDC80/Nuf2/SPC24/SPC25, predicts poor survival in HCC [ 22 ]. Recent literature reported that overexpression of SPC25 was related to poor prognosis of HCC via promoting tumor growth and metastasis [ 23 , 24 ]. However, the detailed expression status of SPC25 in HCCC and the biological function of SPC25 in HCC cells remain unclear.…”

Weighted Gene Coexpression Network Analysis of Key Genes Controlling Cancer Stem Cell Characteristics by Mrnasi in Colon Adenocarcinoma

“…The protein encoded by SPC25 was involved in kinetochore-microtubule interaction and spindle checkpoint function. Previous studies have shown that SPC25 upregulation increases CSCs properties and predicted poor prognosis in lung adenocarcinoma, breast cancer, hepatocellular carcinoma and head and neck cancer [46][47][48][49][50].In this study, we innovatively found that SPC25 was highly related to COAD stem cell properties. No studies have found the role of SPC25 in colon cancer.…”